Biomarkers, such as CA-125 and human epididymis protein (HE4), showing low sensitivity and non-specific symptoms in the early stages of disease, remain the primary limitations of early detection of ovarian cancer, despite advances [5]. This evidence concerns the gene MUC16 and ovarian carcinoma.